HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Church & Dwight Shapes Potential OTC Play On Gummy Format

This article was originally published in The Tan Sheet

Executive Summary

The firm says sales of L’il Critters children’s and Vitafusion adults’ gummy vitamin lines increased more than 7% in its fiscal 2015 third quarter from the year-ago period as production and distribution began recovering from disruptions that restrained sales in the previous quarter.

You may also be interested in...



Traditional But Trendy: Capsules And Tablets Lead VMS Delivery Formats Despite Gummy Growth

Natural Marketing Institute survey found capsules (42%) and tablets (41%) are most popular supplement formats followed by gummies (35%). Results presented during a Council for Responsible Nutrition webinar showed younger consumers are willing to try formats such as tinctures, oral sprays and tablets.

Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx

C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.

Demand For Vitafusion, L’il Critters Gummy Lines Exceeds Church & Dwight Capacity, Drive Q3 Growth

Church & Dwight reports strong consumption of its Vitafusion and L’il Critters vitamins drove personal care product division sales up 24.5% and prompted it to use contract manufacturing to meet demand. The firm also adjusted its net sales outlook for the year to 11% and its EPS to $2.79-$2.81.

Topics

Related Companies

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel